← Back to Search

Stem Cell Therapy

Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose for Diabetic Kidney Disease

Phase 1

Waitlist Available

Led By LaTonya J Hickson, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline through month 15

Awards & highlights

Study Summary

This trial will test if intra-arterially delivered autologous adipose tissue-derived mesenchymal stem/stromal cells are safe and effective in treating patients with progressive diabetic kidney disease.

Eligible Conditions

Diabetic Kidney Disease
Type 1 Diabetes
Type 2 Diabetes
Chronic Kidney Disease
Kidney Failure

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline through month 15

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline through month 15

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through month 15 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse Events

Secondary outcome measures

Kidney Function

Trial Design

2Treatment groups

Experimental Treatment

Group I: Lower Dose MSCExperimental Treatment1 Intervention

This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.

Group II: Higher Dose MSCExperimental Treatment1 Intervention

This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Regenerative Medicine MinnesotaUNKNOWN

Mayo ClinicLead Sponsor

3,205 Previous Clinical Trials

3,766,782 Total Patients Enrolled

LaTonya J Hickson, MDPrincipal InvestigatorMayo Clinic

2 Previous Clinical Trials

60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must be met in order to participate in this clinical investigation?

"Eligible applicants must be between 45 and 75 years old, with diabetic nephropathies as their primary kidney disease. Any suspected concomitant diseases beyond hypertension disqualify them from the trial. The study is currently recruiting 30 participants meeting these requirements."

Answered by AI

What is the participant capacity of this clinical trial?

"Affirmative. The clinical trial's information hosted on clinicaltrials.gov proposes that the study, which commenced on October 23rd 2019, is presently recruiting participants. Approximately 30 patients must be enrolled from a single site."

Answered by AI

Are participants of at least 30 years old eligible for this research?

"According to the entry requirements for this research, individuals must be between 45 and 75 years old in order to qualify as a participant."

Answered by AI

Is the usage of Autologous adipose-derived mesenchymal stem/stromal cells (MSC) at a reduced dosage sanctioned by the FDA?

"As a Phase 1 trial, with limited data demonstrating its efficacy and safety, the Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Low Dose has been rated as a score of 1 by our team at Power."

Answered by AI

Are there any opportunities to partake in this investigation currently?

"Affirmative. According to the records on clinicaltrials.gov, this trial is actively signing up participants and was originally posted on October 23rd 2019. 30 patients need to be enrolled from a single medical centre before the study concludes."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

LaTonya J. Hickson 2019. "Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03840343.